What is known about pediatric antiphospholipid syndrome?

Pier Luigi Meroni, Lorenza Maria Argolini, Irene Pontikaki

Research output: Contribution to journalReview articlepeer-review


Introduction: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity associated with the persistent presence of antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-β2 glycoprotein I antibodies (aβ2GPI). Areas covered: APS is considered as the most common acquired hypercoagulation state of autoimmune origin in children. Unfortunately, data about incidence, prevalence, thrombosis risk and effective treatment in paediatric APS are limited and unmethodical. Expert commentary: This review summarizes recent clinical, laboratory and therapy characterization of paediatric APS and emphasizes the differences between paediatric and adult populations.

Original languageEnglish
Pages (from-to)977-985
Number of pages9
JournalExpert Review of Hematology
Issue number10
Publication statusPublished - Oct 2 2016


  • De novo aPL
  • neonatal thrombosis
  • Paediatric antiphospholipid syndrome
  • Paediatric CAPS
  • Ped APS Registry
  • thrombosis in children

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'What is known about pediatric antiphospholipid syndrome?'. Together they form a unique fingerprint.

Cite this